DECA - Dividend announcements

As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexam

Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion.  The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dex

Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA) ("SPAC") announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for th